News & Updates

Back to All

Kedalion Therapeutics Presents Data from AcuStream™ Studies at the Ophthalmology Innovation Summit (OIS)

Washington, DC, April 12, 2018 – Kedalion Therapeutics, Inc., a clinical-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, announced results from two Phase I studies with its AcuStream platform. These results were presented today in an industry showcase at the Ophthalmology Innovation Summit (OIS) in Washington, DC.

“We are delighted to have been invited to present our data to this group of ophthalmology experts, and we are very pleased that our data sets validate the benefits of our AcuStream technology,” said Peter Noymer, Ph.D., President and Chief Executive Officer, Kedalion. “These proof-of-concept clinical studies demonstrate a clear path forward for the ongoing development of AcuStream, based on statistically similar therapeutic effects compared to standard eye drops but with a substantially lower dose and with increased patient comfort and reduced adverse events.”

The first study was a single-day, single-dose study of topical delivery of a tropicamide-phenylephrine combination for pupil dilation. 20 subjects (40 eyes) were randomized to receive either a 30-microliter dose using standard eye drops or a 9-microliter dose using the AcuStream technology. In this study, a statistically similar pupil dilation effect was observed with a 70% lower dose of drug when using the AcuStream compared to standard eye drops. In addition, subjects reported 43% increased comfort with AcuStream and 35% lower incidence rate of adverse events with AcuStream compared with standard eye drops.

The second study was a single-day, single-dose study of topical delivery of latanoprost for intraocular pressure reduction. 18 subjects (36 eyes) were randomized to receive either a 30-microliter dose using standard eye drops or a 9-microliter dose using the AcuStream technology. In this study, a statistically similar reduction in intraocular pressure (IOP) was achieved with 70% lower dose of drug when using the AcuStream compared to standard latanoprost eye drops.

 

About Kedalion Therapeutics
Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable effect with up to an 80% reduction in dose compared to standard eye drops. Kedalion is based in Menlo Park, CA. For more information, visit www.kedalionthera.com.

 

Download a PDF of this press release >